Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to reduced caloric intake ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

For more than three decades, the pharmaceutical sector has been protected from tariffs by a World Trade Organization ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

The attorneys general sent a letter saying the FDA needs to take action because high demand for the weight loss drugs paired with shortages has created a market for counterfeits.

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...

Nvidia’s momentum has been weighed down by cooling AI hype and broader market instability. Despite reporting blockbuster Q4 ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.